Endometrial Cancer – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Endometrial Cancer – Pipeline Review, H1 2020’, provides an overview of the Endometrial Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Endometrial Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Endometrial Cancer and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Endometrial Cancer

– The report reviews pipeline therapeutics for Endometrial Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Endometrial Cancer therapeutics and enlists all their major and minor projects

– The report assesses Endometrial Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Endometrial Cancer

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Endometrial Cancer

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Endometrial Cancer pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Aadi Bioscience Inc

Ability Pharmaceuticals SL

Abpro Corp

Acepodia Biotech Inc

Acrotech Biopharma LLC

Adlai Nortye Biopharma Co Ltd

Advenchen Laboratories LLC

Agenus Inc

Almac Discovery Ltd

Amgen Inc

Apexian Pharmaceuticals Inc

Apexigen Inc

Apollomics Inc

Arcus Biosciences Inc

Arrien Pharmaceuticals LLC

Ascenta Therapeutics Inc

AstraZeneca Plc

Bantam Pharmaceutical LLC

Bavarian Nordic A/S

Bayer AG

BeiGene Ltd

Beijing Neoantigen Biotechnology Co Ltd

Bicycle Therapeutics Plc

Bio-Path Holdings Inc

BioMed Valley Discoveries Inc

BioNTech SE

Black Diamond Therapeutics Inc

Boehringer Ingelheim International GmbH

Bristol-Myers Squibb Co

Byondis BV

Carrick Therapeutics Ltd

Celon Pharma SA

Celsion Corp

Checkpoint Therapeutics Inc

Clovis Oncology Inc

Compugen Ltd

Context Therapeutics LLC

Corvus Pharmaceuticals Inc

Cotinga Pharmaceuticals Inc

Cue Biopharma Inc

Cyclacel Pharmaceuticals Inc

Daiichi Sankyo Co Ltd

Deciphera Pharmaceuticals Inc

Eisai Co Ltd

Eli Lilly and Co

Elicio Therapeutics

ENB Therapeutics LLC

Epizyme Inc

Esperance Pharmaceuticals Inc

Esperas Pharma Inc

EstryX Pharma Ltd

Exelixis Inc

F. Hoffmann-La Roche Ltd

Fujifilm Holdings Corp

GamaMabs Pharma SA

Genmab AS

GlaxoSmithKline Plc

Gradalis Inc

Hanmi Pharmaceuticals Co Ltd

Harbin Gloria Pharmaceuticals Co Ltd

Hebei Senlang Biotechnology Inc Ltd

Horizon Therapeutics Plc

Hutchison MediPharma Ltd

Immunocore Ltd

ImmunoGen Inc

Immunomedics Inc

Incyte Corp

Innate Pharma SA

Innovent Biologics Inc

Jiangsu Hengrui Medicine Co Ltd

Karyopharm Therapeutics Inc

Komipharm International Co Ltd

Laekna Therapeutics Shanghai Co Ltd

Leap Therapeutics Inc

Merck & Co Inc

Merck KGaA

Mereo Biopharma Group Plc

Mersana Therapeutics Inc

Merus NV

Millennium Pharmaceuticals Inc

Moderna Inc

Molecular Partners AG

Molecular Templates Inc

NeoTX Therapeutics Ltd

NextCure Inc

Northlake International LLC

Novartis AG

NovaTarg Therapeutics Inc

Oncoceutics Inc

Oncologie Inc

Oncology Venture U.S. Inc

OncoResponse Inc

Ono Pharmaceutical Co Ltd

Orano Med LLC

Pfizer Inc

Pharma Mar SA

Pieris Pharmaceuticals Inc

PRISM Pharma Co Ltd

PTC Therapeutics Inc

Puma Biotechnology Inc

Samumed LLC

Sanofi

SELLAS Life Sciences Group Inc

Shanghai Junshi Bioscience Co Ltd

Splash Pharmaceuticals Inc

Spring Bank Pharmaceuticals Inc

SpringWorks Therapeutics Inc

Sutro Biopharma Inc

Syndax Pharmaceuticals Inc

Taiho Pharmaceutical Co Ltd

Unum Therapeutics Inc

Vyriad Inc

Xencor Inc

Zymeworks Inc

Table of Contents

Table of Contents

Introduction

Endometrial Cancer - Overview

Endometrial Cancer - Therapeutics Development

Endometrial Cancer - Therapeutics Assessment

Endometrial Cancer - Companies Involved in Therapeutics Development

Endometrial Cancer - Drug Profiles

Endometrial Cancer - Dormant Projects

Endometrial Cancer - Discontinued Products

Endometrial Cancer - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Endometrial Cancer, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..3), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..4), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..5), H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Endometrial Cancer – Pipeline by Aadi Bioscience Inc, H1 2020

Endometrial Cancer – Pipeline by Ability Pharmaceuticals SL, H1 2020

Endometrial Cancer – Pipeline by Abpro Corp, H1 2020

Endometrial Cancer – Dormant Projects, H1 2020

Endometrial Cancer – Discontinued Products, H1 2020

Endometrial Cancer – Discontinued Products, H1 2020 (Contd..1), H1 2020

List of Figures

List of Figures

Number of Products under Development for Endometrial Cancer, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Top 10 Routes of Administration, H1 2020

Number of Products by Stage and Top 10 Routes of Administration, H1 2020

Number of Products by Top 10 Molecule Types, H1 2020

Number of Products by Stage and Top 10 Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports